GI / Hepatology
Hepatocellular Carcinoma — Surveillance & Management
EASL 2018 / BSG — surveillance criteria, BCLC staging, treatment by stage (resection, ablation, TACE, systemic, transplant).
Source: EASL 2018; BSG 2024; BCLC 2022
Step 1 of ~8
info
Surveillance — Who?
Surveillance: USS abdomen + AFP every 6 months for:
• All patients with cirrhosis (any cause).
• Chronic hepatitis B (without cirrhosis): Asians men >40, Asian women >50, African >20, family history HCC, HIV co-infection, persistent inflammatory activity.
• Chronic hepatitis C with advanced fibrosis (F3) post-SVR.
Surveillance not cost-effective in non-cirrhotic NAFLD without other risk factors.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Prednisolone (Sudden Sensorineural Hearing Loss) · Corticosteroid (systemic — SSNHL treatment)
- Ganciclovir · Antiviral — CMV Treatment (IV) / Retinitis / Transplant
- Silicone Gel / Sheeting (Scar Management) · Medical Device / Topical Scar Treatment
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Dexamethasone (ICU / ARDS) · Systemic Corticosteroid
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
Decision support only. Always apply local guidelines and clinical judgement.